VivoSeq
Cardiovascular

Aortic Valve Replacement

0

Pipeline Programs

4

Active Trials

0

Companies Involved

Aortic Valve Replacement is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

80/100

Attrition Rate

6/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

16

clinical trials

Completed8 · 50%
Recruiting2 · 13%
Unknown status2 · 13%
Suspended1 · 6%
Terminated1 · 6%
Not yet recruiting1 · 6%
Other1 · 6%

Trial Activity

16 trials

EMPagliflozin After Aortic Valve Replacement
Active, not recruiting··Phase 4·NCT06171802·205 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)